All In Biotech

NDA 219500 · Corstasis Therap

Enbumyst

Bumetanide · Nasal · Loop Diuretic

Last checked: Nov 20, 2026Latest source record: Sep 12, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Sep 12, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

45

9 Phase 3, 9 recruiting

FAERS reports

20,456

15,798 serious, 3,059 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 12, 2025 Original approval · Type 3 - New Dosage Form LetterLabel
1 products under this application
  • ENBUMYST · BUMETANIDE 0.5MG/SPRAY · SPRAY, NASAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Bumetanide" as an intervention, any sponsor and status, largest first.

All 45 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea1,981
  • acute kidney injury1,414
  • fatigue1,340
  • death1,290
  • diarrhoea1,251
  • nausea1,149
  • dizziness1,004
  • headache984
  • pneumonia847
  • hypotension760
  • renal failure745
  • fall735

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004176
2005224
2006205
2007195
2008202
2009209
2010260
2011357
2012446
2013465
2014609
2015931
20161,178
20171,236
20181,430
20191,547
20201,562
20211,172
20221,111
20231,478
20241,886
20252,037
20261,540

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 179 on PubMed

Sponsor: Corstasis Therap

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.